CAST Bio

CAST Bio is a preclinical-stage biotechnology company pioneering Cancer Stromal Targeting (CAST), a differentiated approach to antibody-drug conjugate development. Unlike conventional ADCs that depend primarily on tumor cell-surface antigens, its approach is designed to target the tumor stroma and enable localized payload release within the tumor microenvironment. By turning a defining feature of hard-to-treat solid tumors into a therapeutic opportunity, CAST Bio aims to expand the reach of ADC medicines and deliver meaningful new treatment options for patients whose cancers remain inadequately served by current therapies.